Immunity, Inflammation and Disease, Volume 13, Issue 1, January 2025.Our study provides a comprehensive depiction of the clinical symptoms experienced by healthcare workers during and after SARS‐CoV‐2 infection in China's Omicron wave, shedding light on the intricate interplay between these symptoms and offering novel insights into the physiological impact of SARS‐CoV‐2 on human health.
Haoling Tang +11 more
wiley +1 more source
The Role of Ursodeoxycholic Acid Administration During the COVID‐19 Pandemic: A Questionnaire Survey
Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2025, Issue 1, 2025.In December 2022, China classified COVID‐19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID‐19. The objective of this questionnaire was to assess the infection status in the COVID‐19 pandemic since December in Henan Province, China, and the prevalence of infection in people who were taking ...
Cheng Zhou +7 more
wiley +1 more source
Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies
Influenza and Other Respiratory Viruses, Volume 18, Issue 12, December 2024.ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive.
Nida Kalam +1 more
wiley +1 more source
Health Science Reports, Volume 7, Issue 11, November 2024.ABSTRACT Background and Aims Early stage administration of Paxlovid has been shown to improve the prognosis of mild to moderate COVID‐19 patients with high risk. However, few evidence was validated in severe COVID‐19 patients with hypoxemia. It is also unclear whether delayed usage of Paxlovid affected prognosis in COVID‐19 patients or not.
Yu‐Ji Wang +8 more
wiley +1 more source
Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge. [PDF]
Front ImmunolBackgroundLittle is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.MethodsThis study enrolled patients diagnosed with COVID-19 from December 2022 to February 2023.
Qiu M +5 more
europepmc +4 more sources
Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study [PDF]
, 2023 Hui Yang +10 more
openalex +1 more source
The Clinical Respiratory Journal, Volume 18, Issue 7, July 2024.We performed a meta‐analysis with 24 observational studies concerning the effect of Chinese COVID‐19 patients with azvudine. We discovered that azvudine offers a good protective effect and safety profile, significantly reducing mortality of COVID‐19 patients.
Tao Dong +6 more
wiley +1 more source
Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study [PDF]
, 2023 Guangtong Deng +11 more
openalex +3 more sources
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment [PDF]
Signal Transduction and Targeted Therapy, 2020 Yu, Bin, Chang, Junbiao
openaire +2 more sources
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981] [PDF]
, 2023 Yuming Sun +6 more
openalex +1 more source